SAN DIEGO, April 5, 2019 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its LessRay® radiation reduction and workflow enhancement platform was voted a gold winner in the advanced surgical instruments category at the 2019 Edison Awards™ held in New York City on April 4.
The LessRay platform is built on a proprietary algorithm that captures and enhances low-dose, low-quality images to produce images with similar diagnostic capabilities as conventional full-dose images. This technology has the ability to reduce radiation emissions to the operating room (OR) staff and patient by 75 percent compared to standard fluoroscopy.1 Also included in this multi-functional platform are tools designed to increase OR efficiency through streamlined surgical workflow and redefined anatomical visualization. LessRay is part of the Surgical Intelligence™ ecosystem, an assembly of technologies to help surgeons deliver safer, faster and smarter surgery. LessRay will be integrated with neuromonitoring, planning, rod-bending, navigation and automation to create the Pulse™ surgical automation platform, set to launch later in 2019, helping bring Surgical Intelligence to life in the OR.
Increased radiation exposure and limited imaging capabilities are some of the many barriers faced in adopting minimally invasive surgery (MIS). LessRay is designed to maintain the diagnostic image quality and anatomical visualization necessary to perform MIS procedures. This platform further accelerates the adoption of MIS to enable potential patient benefits, including decreased blood loss, lower risk of infection and faster recovery time.
“Studies show surgeons can receive their lifetime occupational radiation limit within the first decade of their career, and NuVasive is proud to play an integral role in building a safer OR experience for surgeons, staff and patients,” said Matt Link, president of NuVasive. “We are honored to be recognized by the Edison Awards for the LessRay platform. This is a meaningful testament to NuVasive’s ongoing commitment and leadership in innovating technologies to deliver better, more reproducible clinical outcomes in spine surgery.”
The Edison Awards is an annual competition designed to honor excellence in new product and service development, marketing, human-centered design and innovation. Winners represent “game changing” products, services, excellence and leadership in innovation around four criteria: Concept, Value, Delivery and Impact. A panel of more than 3,000 leading business executives including past award winners, academics and leaders in the fields of product development, design, engineering, science and medicine, judged the ballot of nominees for the Edison Awards.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
1 Wang TY, Farber SH, Perkins SS, et al. An internally randomized control trial of radiation exposure using ultra-low radiation imaging (ULRI) versus traditional C-arm fluoroscopy for patients undergoing single-level minimally invasive transforaminal lumbar interbody fusion. Spine 2017;42(4);217-23.
SOURCE NuVasive, Inc.